CANDEL THERAPEUTICS, INC. Increase Decrease In Operating Lease Liability
CANDEL THERAPEUTICS, INC. (CADL) reported Increase Decrease In Operating Lease Liability of -$218.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-13
- CANDEL THERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$110.00K.
- CANDEL THERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$108.00K.
- CANDEL THERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$105.00K.
- CANDEL THERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$129.00K.
- CANDEL THERAPEUTICS, INC. increase decrease in operating lease liability for fiscal 2025 was -$509.00K.
- CANDEL THERAPEUTICS, INC. increase decrease in operating lease liability for fiscal 2024 was -$513.00K.
- CANDEL THERAPEUTICS, INC. increase decrease in operating lease liability for fiscal 2023 was -$464.00K.
- CANDEL THERAPEUTICS, INC. increase decrease in operating lease liability for fiscal 2022 was -$464.00K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$110.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$218.00K 10-Q · filed 2026-08-13 | -$323.00K derived: sum of 3 quarters · filed 2026-08-13 | -$452.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$108.00K 10-Q · filed 2026-05-14 | -$213.00K derived: sum of 2 quarters · filed 2026-05-14 | -$342.00K derived: sum of 3 quarters · filed 2026-05-14 | -$481.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$105.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$234.00K derived: sum of 2 quarters · filed 2026-03-12 | -$373.00K derived: sum of 3 quarters · filed 2026-08-13 | -$509.00K 10-K · filed 2026-03-12 |
| 2025-09-30 | -$129.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$268.00K derived: sum of 2 quarters · filed 2026-08-13 | -$404.00K 10-Q · filed 2025-11-13 | -$538.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$139.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$275.00K 10-Q · filed 2026-08-13 | -$409.00K derived: sum of 3 quarters · filed 2026-08-13 | -$539.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$136.00K 10-Q · filed 2026-05-14 | -$270.00K derived: sum of 2 quarters · filed 2026-05-14 | -$400.00K derived: sum of 3 quarters · filed 2026-05-14 | -$526.00K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$134.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$264.00K derived: sum of 2 quarters · filed 2026-03-12 | -$390.00K derived: sum of 3 quarters · filed 2026-03-12 | -$513.00K 10-K · filed 2026-03-12 |
| 2024-09-30 | -$130.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$256.00K derived: sum of 2 quarters · filed 2025-11-13 | -$379.00K 10-Q · filed 2025-11-13 | -$500.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$126.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$249.00K 10-Q · filed 2025-08-14 | -$370.00K derived: sum of 3 quarters · filed 2025-08-14 | -$488.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$123.00K 10-Q · filed 2025-05-13 | -$244.00K derived: sum of 2 quarters · filed 2025-05-13 | -$362.00K derived: sum of 3 quarters · filed 2025-05-13 | -$475.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$121.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$239.00K derived: sum of 2 quarters · filed 2025-03-13 | -$352.00K derived: sum of 3 quarters · filed 2025-03-13 | -$464.00K 10-K · filed 2025-03-13 |
| 2023-09-30 | -$118.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$231.00K derived: sum of 2 quarters · filed 2024-11-14 | -$343.00K 10-Q · filed 2024-11-14 | -$465.00K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$113.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$225.00K 10-Q · filed 2024-08-13 | -$347.00K derived: sum of 3 quarters · filed 2024-08-13 | -$464.00K derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$112.00K 10-Q · filed 2024-05-14 | -$234.00K derived: sum of 2 quarters · filed 2024-05-14 | -$351.00K derived: sum of 3 quarters · filed 2024-05-14 | -$464.00K derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$122.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$239.00K derived: sum of 2 quarters · filed 2024-03-28 | -$352.00K derived: sum of 3 quarters · filed 2024-03-28 | -$464.00K 10-K · filed 2024-03-28 |
| 2022-09-30 | -$117.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$230.00K derived: sum of 2 quarters · filed 2023-11-09 | -$342.00K 10-Q · filed 2023-11-09 | |
| 2022-06-30 | -$113.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$225.00K 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | -$112.00K 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |